Prolonged PT and aPTT in a Preoperative Patient
A 70-year-old woman is scheduled for elective knee replacement. Preoperative labs show PT 18.5 seconds (reference 11-14), INR 1.6, aPTT 45 seconds (reference 25-35), platelet count 150 x 10^9/L, and fibrinogen 300 mg/dL. She has no history of bleeding or bruising, and no family history of bleeding. She takes no medications except occasional acetaminophen. She has not taken antibiotics recently. The surgeon is concerned about bleeding risk and asks for a hematology consult. The hematologist orders mixing studies. The immediate mixing study (patient plasma + normal plasma 1:1) shows PT 14.5 seconds (normal 11-14) and aPTT 38 seconds (normal 25-35). The incubated mixing study (2 hours at 37°C) shows PT 17.0 seconds and aPTT 44 seconds.
1. Interpret the mixing study results and determine the likely cause of the prolonged PT and aPTT.
Read the worked answer
The immediate mixing study shows partial correction of both PT and aPTT, but not complete correction. The incubated mixing study shows worsening of both PT and aPTT, suggesting a time-dependent inhibitor. However, the pattern is not typical for a classic factor inhibitor (which usually shows no correction immediately and may show further prolongation on incubation). The partial correction and then prolongation on incubation could indicate a weak inhibitor or a factor deficiency with an inhibitor. Given the patient's age and lack of bleeding history, an acquired factor inhibitor, such as factor VIII inhibitor, is possible but less likely without bleeding. Another possibility is a lupus anticoagulant, which can cause prolonged PT and aPTT, but typically the mixing study shows correction immediately and may show prolongation on incubation due to the antibody's effect. However, lupus anticoagulant usually prolongs aPTT more than PT and is associated with thrombosis, not bleeding. The patient has no bleeding history, so a lupus anticoagulant is plausible. However, the PT is also prolonged, which can occur with lupus anticoagulant but is less common. Other causes include factor deficiency (e.g., factor VII, X, V, II) or vitamin K deficiency, but the patient has no risk factors. Liver disease is unlikely. The mixing study results: immediate mixing shows partial correction, which suggests a factor deficiency or a weak inhibitor. The incubated mixing study shows prolongation, which suggests a time-dependent inhibitor. The most likely cause is a lupus anticoagulant, which can show this pattern (immediate correction, then prolongation on incubation due to the antibody's effect). However, the PT prolongation is significant. Another possibility is an acquired factor inhibitor to a factor in the common pathway (e.g., factor V inhibitor), which can occur after surgery or with antibiotics, but the patient has no such history. The hematologist should order specific factor assays (VIII, IX, XI, XII, VII, X, V, II) and tests for lupus anticoagulant (dRVVT, hexagonal phase phospholipid, platelet neutralization). The patient's bleeding risk should be assessed; if no bleeding history, the risk may be low. The surgery may proceed with caution, but the hematologist should be consulted.
2. What further testing should be performed, and how should the results guide perioperative management?
Read the worked answer
Further testing should include: (1) Specific factor assays for factors VIII, IX, XI, XII, VII, X, V, and II to identify any deficiency or inhibitor. (2) Lupus anticoagulant testing: dRVVT with confirmatory test, hexagonal phase phospholipid neutralization, and platelet neutralization procedure. (3) Anticardiolipin antibodies and anti-beta2 glycoprotein I antibodies to assess for antiphospholipid syndrome. (4) Mixing study with additional dilutions (e.g., 1:2, 1:4) to better characterize an inhibitor. (5) Factor VIII inhibitor Bethesda assay if factor VIII is low. (6) von Willebrand factor testing if factor VIII is low. The results will guide management: if a lupus anticoagulant is confirmed and the patient has no bleeding history, the risk of bleeding is low, and surgery can proceed without specific treatment, but the surgeon should be aware of the laboratory abnormality. If a factor deficiency is found, factor replacement may be needed. If an inhibitor is found, management may include factor bypassing agents or immunosuppression, and surgery may be postponed. The patient should be evaluated by a hematologist for bleeding risk and possibly for thrombotic risk if antiphospholipid syndrome is diagnosed. Preoperative planning should include communication between the surgeon, hematologist, and anesthesiologist.